γδ T cells are a small but distinctive subset of T lymphocytes that 𝘣𝘳𝘪𝘥𝘨𝘦 𝘪𝘯𝘯𝘢𝘵𝘦 𝘢𝘯𝘥 𝘢𝘥𝘢𝘱𝘵𝘪𝘷𝘦 𝘪𝘮𝘮𝘶𝘯𝘪𝘵𝘺. Unlike conventional αβT cells, 𝘵𝘩𝘦𝘺 𝘳𝘦𝘴𝘱𝘰𝘯𝘥 𝘳𝘢𝘱𝘪𝘥𝘭𝘺 𝘵𝘰 𝘤𝘦𝘭𝘭𝘶𝘭𝘢𝘳 𝘴𝘵𝘳𝘦𝘴𝘴 𝘢𝘯𝘥 𝘵𝘳𝘢𝘯𝘴𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯, making them critical in early immune surveillance. Their unique biology and cytotoxic potential have attracted attention in immunotherapy research, particularly in oncology [1]. 

𝗡𝗼𝗻-𝗖𝗹𝗮𝘀𝘀𝗶𝗰𝗮𝗹 𝗙𝗲𝗮𝘁𝘂𝗿𝗲𝘀 
What distinguishes γδ T cells as non-classical T cells is their 𝘢𝘯𝘵𝘪𝘨𝘦𝘯 𝘳𝘦𝘤𝘰𝘨𝘯𝘪𝘵𝘪𝘰𝘯 𝘪𝘯𝘥𝘦𝘱𝘦𝘯𝘥𝘦𝘯𝘵 𝘰𝘧 𝘔𝘏𝘊 𝘮𝘰𝘭𝘦𝘤𝘶𝘭𝘦𝘴. This allows them to detect stressed, infected, or transformed cells without requiring classical antigen presentation. Furthermore, 𝘵𝘩𝘦𝘺 𝘤𝘢𝘯 𝘴𝘦𝘤𝘳𝘦𝘵𝘦 𝘤𝘺𝘵𝘰𝘬𝘪𝘯𝘦𝘴 𝘢𝘯𝘥 𝘤𝘩𝘦𝘮𝘰𝘬𝘪𝘯𝘦𝘴 𝘵𝘩𝘢𝘵 𝘮𝘰𝘥𝘶𝘭𝘢𝘵𝘦 𝘰𝘵𝘩𝘦𝘳 𝘪𝘮𝘮𝘶𝘯𝘦 𝘤𝘦𝘭𝘭𝘴, acting both as effectors and regulators. [1,2].  

𝗖𝗔𝗥-𝗧 𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗮𝗻𝗱 𝗔𝗱𝘃𝗮𝗻𝘁𝗮𝗴𝗲𝘀 
Unlike conventional αβ CAR-T cells, γδ CAR-T cells 𝘳𝘦𝘵𝘢𝘪𝘯 𝘯𝘢𝘵𝘶𝘳𝘢𝘭 𝘵𝘶𝘮𝘰𝘳 𝘳𝘦𝘤𝘰𝘨𝘯𝘪𝘵𝘪𝘰𝘯 𝘸𝘩𝘪𝘭𝘦 𝘢𝘭𝘴𝘰 𝘤𝘢𝘳𝘳𝘺𝘪𝘯𝘨 𝘦𝘯𝘨𝘪𝘯𝘦𝘦𝘳𝘦𝘥 𝘳𝘦𝘤𝘦𝘱𝘵𝘰𝘳𝘴, which may enhance specificity and reduce the risk of graft-versus host disease in allogeneic settings. Their 𝘳𝘢𝘱𝘪𝘥 𝘤𝘺𝘵𝘰𝘵𝘰𝘹𝘪𝘤𝘪𝘵𝘺, 𝘭𝘰𝘸 𝘥𝘦𝘱𝘦𝘯𝘥𝘦𝘯𝘤𝘦 𝘰𝘯 𝘔𝘏𝘊, 𝘢𝘯𝘥 𝘢𝘣𝘪𝘭i𝘵𝘺 𝘵𝘰 𝘵𝘳𝘢𝘧𝘧𝘪𝘤 𝘵𝘰 𝘴𝘰𝘭𝘪𝘥 𝘵𝘶𝘮𝘰𝘳𝘴 make them attractive candidates for next-generation cellular immunotherapies [2,3]. 

𝗚𝗲𝗿𝗺𝗮𝗻 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 
Prof. Dieter Kabelitz (University of Lübeck) – studies γδ T cell biology and their pharmacological modulation in cancer immunotherapy [4]. 
Prof. Stefan Endres (LMU Munich) – focuses on in vitro expansion and activation protocols to improve γδ T cell cytotoxicity [5]. 
FOR2799 DFG Research Group – investigates the role of galectin-3 in modulating γδ T cell function within the tumor microenvironment [6]. 

𝗦𝗽𝗲𝗰𝘂𝗹𝗮𝘁𝗶𝘃𝗲 𝗛𝘆𝗽𝗼𝘁𝗵𝗲𝘀𝗶𝘀 
γδ T cells may act as immune modulators within the TME. They could influence DC activation and enhance the recruitment of other lymphocytes. γδ T cells might synergize with checkpoint inhibitors or other CAR-T cell approaches [7]. 

Stay tuned for 𝗗𝗮𝘆 𝟮𝟰: 𝗢𝘃𝗲𝗿𝘃𝗶𝗲𝘄 𝗿𝗲𝗰𝗮𝗽 𝗼𝗳 𝗰𝗲𝗹𝗹 𝘁𝘆𝗽𝗲𝘀 

𝗥𝗲𝗳𝗲𝗿𝗲𝗻𝗰𝗲𝘀 
1. DOI: 10.1038/s41423-020-0504-x 
2. doi: 10.1016/j.canlet.2016.07.001 
3. https://doi.org/10.3389/fimmu.2025.1554541 
4.  DOI: 10.1038/s41392-023-01653-8 
5. https://pubmed.ncbi.nlm.nih.gov/11956095/ 
6. https://www.for2799.de/ 
7. DOI: 10.1186/s12943-023-01722-0   

#100DaysOfImmunology #GammaDeltaTCells #NonClassicalTCells #CAR_T #Immunotherapy #CancerTherapy #GermanResearch #CellTherapy #ImmuneModulation #NextGenImmunotherapy